Atipamezole - CAS 104054-27-5
Catalog number: 104054-27-5
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C14H16N2
Molecular Weight:
212.29
COA:
Inquire
Targets:
Adrenergic Receptor
Description:
Atipamezole, a 4-substituted imidazole derivative, is an alpha2-adrenoceptor blocker which could be used for animals to recover from the anesthesia by lowering blood pressure and increasing heart rate and breathing rate.
Publictions citing BOC Sciences Products
  • >> More
Purity:
98%
Appearance:
Off-white to light yellow crystal powder
Synonyms:
atipamezole;4-(2-Ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole;4-(2-Ethyl-2-indanyl)imidazole;MPV-1248
Solubility:
DMSO: ≥ 30 mg/mL
Storage:
-20ºC Freeze
MSDS:
Inquire
Application:
Atipamezole is an alpha2-adrenoceptor blocker which could be used for animals to recover from the anesthesia by lowering blood pressure and increasing heart rate and breathing rate.
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Quantity:
Grams-Kilos
Boiling Point:
367.1ºC at 760 mmHg
Density:
1.115 g/cm3
InChIKey:
HSWPZIDYAHLZDD-UHFFFAOYSA-N
InChI:
InChI=1S/C14H16N2/c1-2-14(13-9-15-10-16-13)7-11-5-3-4-6-12(11)8-14/h3-6,9-10H,2,7-8H2,1H3,(H,15,16)
Canonical SMILES:
CCC1(CC2=CC=CC=C2C1)C3=CN=CN3
1.Blood biochemical changes in mice after administration of a mixture of three anesthetic agents.
Ochiai Y1, Iwano H, Sakamoto T, Hirabayashi M, Kaneko E, Watanabe T, Yamashita K, Yokota H. J Vet Med Sci. 2016 Feb 19. [Epub ahead of print]
Currently, from the viewpoint of animal welfare, anesthesia or analgesia is required during experimental procedures in animals that are likely to cause pain. A part of these anesthetics have been reported to influence a blood biochemical level. It is important for us to understand the effect of the anesthetic on blood biochemistry when we choose the anesthetic agent to be used in experiments. In this study, we examined the blood biochemical changes in mice after administration of a new mixture of three anesthetic agents - medetomidine / midazolam / butorphanol (MMB). We subcutaneously administered two dose combinations of MMB (0.45 / 6 / 7.5 and 0.9 / 12 / 15 mg/kg) in mice, followed by administration of atipamezole, for reversal of anesthetic effects, after 1 hr. Thereafter, blood biochemistry was assessed at 1, 4 and 24 hr after MMB administration. We observed that MMB administration caused a transient increase in blood sugar, inorganic phosphorus, potassium and creatine kinase levels.
2.Dexmedetomidine Postconditioning Reduces Brain Injury after Brain Hypoxia-Ischemia in Neonatal Rats.
Ren X1,2, Ma H3, Zuo Z4. J Neuroimmune Pharmacol. 2016 Mar 2. [Epub ahead of print]
Perinatal asphyxia can lead to death and severe disability. Brain hypoxia-ischemia (HI) injury is the major pathophysiology contributing to death and severe disability after perinatal asphyxia. Here, seven-day old Sprague-Dawley rats were subjected to left brain HI. Dexmedetomidine was given intraperitoneally after the brain HI. Yohimbine or atipamezole, two α2 adrenergic receptor antagonists, were given 10 min before the dexmedetomidine injection. Neurological outcome was evaluated 7 or 28 days after the brain HI. Frontal cerebral cortex was harvested 6 h after the brain HI. Left brain HI reduced the left cerebral hemisphere weight assessed 7 days after the brain HI. This brain tissue loss was dose-dependently attenuated by dexmedetomidine. Dexmedetomidine applied within 1 h after the brain HI produced this effect. Dexmedetomidine attenuated the brain HI-induced brain tissue and cell loss as well as neurological and cognitive dysfunction assessed from 28 days after the brain HI.
3.EFFICACY AND SAFETY OF A MEDETOMIDINE-AZAPERONE-ALFAXALONE COMBINATION IN CAPTIVE WHITE-TAILED DEER (ODOCOILEUS VIRGINIANUS).
Pon K, Caulkett N, Woodbury M. J Zoo Wildl Med. 2016 Mar;47(1):29-37. doi: 10.1638/2015-0121.1.
Alfaxalone is a neurosteroid that interacts with gamma-aminobutyric type A receptors to produce central nervous system depression and muscle relaxation. The effects of alfaxalone vary from sedation to general anesthesia. Alfaxalone is synergistic with other tranquilizers and sedatives and therefore has the potential to improve existing alpha-2 adrenergic agonist-based combinations used for wildlife immobilization. The objective of this study was to determine the efficacy and cardiopulmonary effects of a medetomidine-azaperone-alfaxalone (MAA) combination in captive white-tailed deer (Odocoileus virginianus). Eight captive white-tailed deer were restrained in a drop-floor chute; hand injected i.m. with 0.15 mg/kg medetomidine, 0.2 mg/kg azaperone, and 0.5 mg/kg alfaxalone; and released into a small enclosure for observation. The deer were maintained in lateral recumbency for a total time from postinjection (PI) of the drug of 60 min. At 60 min PI, atipamezole was administered i.
4.The adrenergic α2 antagonist atipamezole alters the behavioural effects of pramipexole and increases pramipexole concentration in blood plasma.
McCormick PN1, Fletcher PJ2, Wilson VS3, Remington GJ4. Life Sci. 2016 Mar 11. pii: S0024-3205(16)30165-5. doi: 10.1016/j.lfs.2016.03.017. [Epub ahead of print]
Pramipexole is a dopaminergic agonist used in Parkinson's disease treatment. It is thought to exert its therapeutic and side effects through actions on dopamine D3 receptors. In a recent study, we found that at doses occupying D3 but not D2 receptors pramipexole reduced locomotion and operant responding for primary and conditioned reinforcement. These effects, however, were not blocked by a D3 receptor antagonist and were present in D3 knockout mice, suggesting non-D3 receptor mechanisms. Among the next highest affinity binding sites of pramipexole are adrenergic α2 receptors. Here we explored α2 receptor involvement in the behavioural effects of pramipexole. We found that the α2 antagonist atipamezole, which was itself behaviourally silent, counteracted pramipexole's reduction of locomotion, but not operant responding for water or a conditioned reinforcer. The resulting behavioural profile was similar to that of a higher dose of pramipexole, leading to the hypothesize that atipamezole mediates its behavioural effects by increasing pramipexole effective dose.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Adrenergic Receptor Products


CAS 73573-87-2 Formoterol

Formoterol
(CAS: 73573-87-2)

Formoterol is a Beta 2 adrenergic receptor agonist. It can be used in the treatment of asthma and COPD. It has an extended duration of action (up to 12 hours) c...

CAS 81732-46-9 Bambuterol HCl

Bambuterol HCl
(CAS: 81732-46-9)

Bambuterol is a long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma.

CAS 804518-03-4 Milveterol hydrochloride

Milveterol hydrochloride
(CAS: 804518-03-4)

Milveterol is a long-acting β(2)-adrenoceptor agonist under the development of GlaxoSmithKline. Phase II trials for the treatment of Chronic obstructive pulmona...

CAS 106401-52-9 Falintolol, (Z)-

Falintolol, (Z)-
(CAS: 106401-52-9)

Falintolol, (Z)- is a novel β-adrenergic antagonist.

CAS 70359-46-5 Brimonidine Tartrate

Brimonidine Tartrate
(CAS: 70359-46-5)

Brimonidine Tartrate is a highly selective α-adrenergic receptor agonist with EC50 of 0.45 nM for the α2A adrenoreceptor, and used to treat open-angle glaucoma ...

CAS 84638-81-3 ZK-90055 hydrochloride

ZK-90055 hydrochloride
(CAS: 84638-81-3)

ZK-90055, a β‐Adrenoceptor agonist, is a B-2 bronchodilator drug.

Dobutamine HCl
(CAS: 49745-95-1)

Dobutamine is a sympathomimetic drug used in the treatment of heart failure and cardiogenic shock. Its primary mechanism is direct stimulation of β1 receptors o...

CAS 208993-54-8 Fiduxosin

Fiduxosin
(CAS: 208993-54-8)

Fiduxosin is a potent antagonist of α1-adrenoceptor, with Ki= 0.160 nM, 24.9 nM, and 0.920 nM for α1a-, α1b-, and α1d-adrenoceptors, respectively. Fiduxosin was...

CAS 530-08-5 Isoetarine

Isoetarine
(CAS: 530-08-5)

Isoetarine is a selective adrenergic beta-2 agonist. It is used as fast acting bronchodilator for emphysema, bronchitis and asthma. It has been listed.

CAS 610309-89-2 Carvedilol Phosphate

Carvedilol Phosphate
(CAS: 610309-89-2)

Carvedilol phosphate hemihydrate is a nonselective beta (β1, β2) blocker and alpha (α1) blocker, inhibits LDL oxidation (IC50 = 3.8 μM).

Nifenalol HCl

The hydrochloride of Nifenalol. Nifenalol is a beta-adrenoceptor antagonist used for the treatment of cardiovascular and cerebrovascular diseases such as hypert...

CAS 34391-04-3 Levalbuterol

Levalbuterol
(CAS: 34391-04-3)

Levalbuterol is a short-acting beta 2 adrenergic agonist. Levalbuterol binds to beta 2 adrenergic receptors and activates intracellular adenyl cyclase to promot...

CAS 6211-32-1 Rauwolscine hydrochloride

Rauwolscine hydrochloride
(CAS: 6211-32-1)

Rauwolscine hydrochloride is the hydrochloride salt of Rauwolscine which is a potent, reversible and specific α2 adrenergic receptor antagonist with a Ki values...

CAS 62929-91-3 Procaterol hydrochloride

Procaterol hydrochloride
(CAS: 62929-91-3)

Procaterol hydrochloride is a long-acting, very potent and specific beta-2-adrenergic receptor agonist. It acts as a vasodialator for long term treatment of ast...

Guanfacine Hydrochloride
(CAS: 249-443-3)

Guanfacine Hydrochloride is a centrally acting alpha-2 adrenergic agonist that has been available as an FDA-approved hypotensive agent for more than two decades...

MK-0634 dihydrochloride
(CAS: 211031-81-1)

MK-0634, also called as L-796568, is an β3 adrenergic receptor agonist that was progressed into clinical studies for the treatment of obesity in the early 2000s...

CAS 58020-43-2 Hoku-81

Hoku-81
(CAS: 58020-43-2)

Hoku 81 is a bronchodilator, and one of the metabolites of tulobuterol.

CAS 19237-84-4 Prazosin Hydrochloride

Prazosin Hydrochloride
(CAS: 19237-84-4)

Prazosin HCl, a quinazoline derivative, is the first of a new chemical class of antihypertensives.

CAS 51-30-9 Isoprenaline HCl

Isoprenaline HCl
(CAS: 51-30-9)

Isoprenaline is a non-selective beta-adrenergic receptor agonist, used for the treatment of bradycardia and heart block. It would increase cAMP levels and activ...

CAS 27912-14-7 Levobunolol hydrochloride

Levobunolol hydrochloride
(CAS: 27912-14-7)

Levobunolol hydrochloride, a beta1- and beta2-adregergic blocking agent, has proved to be an effective ocular hypotensive agent to treat glaucoma.

Chemical Structure

CAS 104054-27-5 Atipamezole

Quick Inquiry

Verification code

Featured Items